Evidence map›Paper›PMID 33187229›Full record

ArticleCancers2020

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.

Safaa M Ramadan, Stefan Suciu, Marian J P L Stevens-Kroef, Roelof Willemze, Sergio Amadori, Theo de Witte, Bob Löwenberg, Petra Muus, Boris Labar, Liv Meert and 7 more

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Safaa M RamadanEORTC Headquarter, 1200 Brussels, Belgium.
Stefan SuciuEORTC Headquarter, 1200 Brussels, Belgium.
Marian J P L Stevens-KroefDepartment of Human Genetics, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-9196-7430
Roelof WillemzeHematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.ORCID 0000-0001-9115-3106
Sergio AmadoriHematology, University Tor Vergata, 00133 Rome, Italy.
Theo de WitteDepartment of Hematology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
Bob LöwenbergHematology, Erasmus University Medical Center Rotterdam, 3000CA Rotterdam, The Netherlands.
Petra MuusDepartment of Hematology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
Boris LabarDepartment of Hematology, University Hospital Center Rebro, 10000 Zagreb, Croatia.
Liv MeertEORTC Headquarter, 1200 Brussels, Belgium.
Gaetan de SchaetzenEORTC Headquarter, 1200 Brussels, Belgium.
Giovanna MeloniDepartment of Cellular Biotechnologies and Hematology, Sapienza University, 00161 Rome, Italy.
Giuseppe LeoneIstituto di Ematologia, Università Cattolica S. Cuore, 00168 Rome, Italy.ORCID 0000-0002-7812-5300
Marco VignettiData Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), 00182 Rome, Italy.
Jean-Pierre MarieDepartment Hematology and Tumor Bank, Saint-Antoine Hospital, AP-HP & University Pierre & Marie Curie, 75571 Paris, France.
Michael LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Faculty of Medicine, 79106 Freiburg, Germany.
Frédéric BaronGIGA-I3, Hematology, University of Liège, 4000 Liège, Belgium.

Funding

Fondation contre le Cancer grant to EORTCFonds De La Recherche Scientifique - FNRS FB Senior research associate mandate
6 · The paper itself

Abstract

We report the outcomes of secondary acute myeloid leukemia (s-AML) patients included in one of 13 European Organisation for Research and Treatment of Cancer (EORTC) collaborative AML trials using intensive remission-induction chemotherapy. Among 8858 patients treated between May 1986 and January 2008, 960 were identified as having s-AML, either after MDS (cohort A;

Indexed as

AMLsecondarytrials

Identifiers

PMID33187229
PMCPMC7697114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.